Rosai-Dorfman Disease clinical trials at UCSF

1 research study open to eligible people

Rosai-Dorfman disease is a disorder where immune cells build up. UCSF uses cobimetinib in a study for both children and adults with Langerhans Cell Histiocytosis. This trial examines the drug's effect on similar histiocytic diseases.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Rosai-Dorfman Disease research studies include .

Last updated: